Document:

EX-10.10

 Exhibit 10.10 

EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (this “Agreement”) executed effective as of the
11th day of July, 2018 (the “Effective Date”), is by and between Nuvalent, Inc., a Delaware corporation (the “Company”), and James Malone
(“Employee”). All capitalized terms not otherwise defined in the text of this Agreement have the meanings attributed to them in Exhibit A, which is incorporated herein by reference. The Company and Employee
are sometimes referred to herein as the “Parties”. 
 RECITALS 

NOW, THEREFORE, in consideration of the promises and the mutual agreements and covenants contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged by the Parties, 
 IT IS HEREBY AGREED AS FOLLOWS: 

ARTICLE I 
 EMPLOYMENT

 1.1    Employment by the Company of Employee and Acceptance by Employee. Effective as of July 11,2018
(the “Start Date”), the Company will employ Employee on an at-will basis in such capacities and upon such terms and conditions as are hereinafter stated. For the avoidance of doubt, it is
agreed and understood that (a) Employee will continue providing services under the Consulting Agreement until the Start Date, unless the Consulting Agreement is terminated before such Start Date, and (b) this Agreement shall be null and
void if the Consulting Agreement terminates before the Start Date. Employee hereby accepts such employment and agrees to devote his entire business time, attention and energies exclusively to the business interests of the Company and shall not
engage in any activity that is harmful to the business, reputation or best interests of the Company or any related entities or companies; provided that the foregoing shall not prevent Employee from (a) participating in charitable, civic,
educational, professional, community and/or industry affairs or (b) managing Employee’s personal and family financial affairs, as long as the activities described in the preceding clauses (a) and (b), individually and in the
aggregate, do not materially interfere with Employee’s duties to the Company. 
 1.2    Term of Employment.
The term of Employee’s employment hereunder (the “Term”) shall commence as of the Start Date and shall continue until terminated pursuant to Article III, whereupon this Agreement and Employee’s employment with the
Company will terminate, except that Articles IV and V of this Agreement shall survive termination and remain in full force and effect thereafter. 

1.3    Position; Duties. Employee shall initially be the Company’s Chief Financial Officer (the
“Position”), and in that capacity, shall report to the Company’s Board of Directors. During the Term, Employee shall faithfully execute all duties, responsibilities and authorities as are as assigned to him. 

1.4    Primary Office Location. Employee’s primary office location shall be at the Company’s
headquarters. 

 ARTICLE II 

COMPENSATION AND OTHER BENEFITS 

2.1     Base Salary. Employee’s annual base salary (the “Base Salary”) shall initially be
$230,000, and shah be payable (net of withholding) in accordance with the Company’s normal payroll practices. Employee’s Base Salary shall be subject to annual review by the Company’s Chief Executive Officer (or a designee thereof) or
the Board (or a committee thereof). 
 2.2    Annual Performance Bonus. With respect to each full fiscal year of
employment completed during the Term, Employee will be eligible for an annual discretionary bonus (an “Annual Bonus”), in an amount, if any, to be determined by the Board in its sole discretion. Subject to the Board’s
discretion to determine the actual amount, such Annual Bonus shall have a target amount equal to thirty percent (30%) of Employee’s Base Salary. Employee’s right to receive the Annual Bonus for any fiscal year is conditioned on his
remaining in the active employ of the Company through the date of payment. 
 2.3    Equity Award. Employee will
receive a stock option award of 0.7% of the fully diluted outstanding equity of the Company (the “Options”) inclusive of a Series A financing up to $50 million. The grant will be subject to the terms and conditions of the
Company’s Equity Incentive Plan and an equity award agreement, which shall be in form and substance acceptable to the Company. The Options will have a strike price set at fair market value to be determined in good faith based on a 409A
valuation in accordance with IRS regulations. The Options shall vest in equal parts on each of the first four anniversaries of the Start Date. Such awards shall continue to be subject to the terms and conditions (including vesting and forfeiture)
provided by the applicable plan documents and award agreements. For the avoidance of doubt, Employee’s employment under this Agreement is a continuation of Employee’s service relationship with the Company for purposes of the continued
vesting of such awards. 
 2.4    Paid Time Off. Employee shall been titled to up to eighteen(18) days per year
of paid time off, which shall begin accruing as of the Start Date at a rate of one and a half (1.5) days per month. Upon accruing eighteen (18) days of paid time off, Employee will cease accruing additional days of paid time off until the
Employee’s accrued paid time off amount is less than eighteen (18) days. 
 2.5    Employee Benefit
Plans. Employee shall be eligible to participate in the employee benefit plans that the Company maintains for the benefit of similarly situated employees, subject to the eligibility and other terms and conditions thereof. Nothing in this
Agreement shall limit the Company’s right to change or cancel any benefit plan at any time and for any reason. 

2.6     Expenses. The Company shall reimburse Employee for all authorized and approved expenses incurred in the
course of the performance of Employee’s duties and responsibilities pursuant to this Agreement, subject to the terms and conditions of the Company’s expense reimbursement policy, as in effect and amended from time to time. 

ARTICLE III 
 EMPLOYMENT
TERMINATION 
 3.1     Right to Terminate. 

(a)    Termination Without Cause. The Company may terminate Employee’s employment and all of the Company’s
obligations under this Agreement at any time and for any reason upon at least two (2) weeks’ prior written notice to Employee. During this notice period, the Company may 

  
 2 

 
request that that Employee not come to the Company’s offices, but Employee shall continue to perform such responsibilities as the Company requests. The Company shall have discretion to
request that Employee separate from service before the end of the notice period, in which case the Company shall continue to pay Employee’s Base Salary through the end of the notice period. If Employee’s employment is terminated under this
Section 3.1(a) after an Annual Bonus for a completed fiscal year has been announced and awarded to Employee but before such Annual Bonus is paid, the Company will pay such Annual Bonus to Employee within thirty
(30) days after the Termination Date. 
 (b)    Termination For Cause. The Company may terminate
Employee’s employment and all of the Company’s obligations under this Agreement at any time for Cause. 

(c)    Termination Due to Death or Disability. Employee’s employment and the Company’s obligations under
this Agreement shall terminate automatically, effective immediately and without any notice being necessary, upon Employee’s death or a determination by the Company that Employee is Disabled. A determination of Disability under this
Section 3.1(c) shall not affect Employee’s right to any disability benefits available under a Company benefit plan; such benefits shall be governed solely by the terms of the applicable plan (if any). 

(d)    Resignation by Employee. Employee may resign from Employee’s employment under this Agreement at any
time and for any reason, subject to providing at least two (2) weeks’ prior written notice. During this notice period, the Company may request that Employee not come to the Company’s offices, but Employee shall continue to perform
such responsibilities as the Company requests. The Company shall have discretion to request that Employee separate from service before the end of the notice period, in which case the Company shall have no obligation to pay Employee for any period
after the requested Termination Date. 
 3.2     Rights Upon Termination. Upon termination of Employee’s
employment under Section 3.1, neither Employee nor Employee’s estate shall have any rights other than as expressly provided in Section 3.1, except for the right to receive payment of
(a) earned but unpaid Base Salary and unused paid time off, in each case accrued through the Termination Date; (b) unreimbursed business expenses; and (c) any vested benefits due under a Company benefit plan. AU payments under this
Section 3.2 shall be paid within thirty (30) days after the Termination Date or at such other time as is prescribed by an applicable benefit plan. 

ARTICLE IV 
 RESTRICTIVE
COVENANTS; COOPERATION; INDEMNIFICATION; REPRESENTATIONS 
 4.1    Restrictive Covenants. 

(a)    Proprietary Information.  

(i)    Employee acknowledges that Employee’s relationship with the Company is one of high trust and
confidence and that in the course of Employee’s employment with the Company, Employee will have access to and contact with Proprietary Information. At all times during the Term and thereafter, Employee will not, except as required in connection
with the performance of Employee’s duties for the Company or as discussed in other provisions of this Section 4.1, disclose or use Proprietary Information for any purposes without written approval by an officer of the Company. 

  
 3 

 (ii)    Any confidentiality and nondisclosure provision
in this Agreement does not prohibit or restrict Employee from responding to any inquiry by, providing testimony to, or otherwise communicating truthfully and in good faith with any other federal, state, or local agency or regulatory authority about
a possible violation of law or regulation. Employee may make such disclosures without providing notice, advance or otherwise, to the Company. Otherwise, in the event that Employee receives a subpoena, request for production, is ordered or otherwise
is compelled to disclose any Proprietary Information, whether in a legal or regulatory proceeding or otherwise, Employee shall, to the extent not prohibited by law, provide the Company with prompt notice of such subpoena, request or order so that
the Company may have the opportunity to seek to prevent disclosure. 
 (iii)    Notwithstanding
Employee’s confidentiality and nondisclosure obligations, Employee is hereby advised as follows pursuant to the Defend Trade Secrets Act: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret
law for the disclosure of a trade secret that (A) is made (I) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (II) solely for the purpose of reporting or
investigating a suspected violation of law, or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for
reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (i) files any document containing the trade secret under
seal; and (ii) does not disclose the trade secret, except pursuant to court order.” 

(iv)    Employee’s obligations under this Section 4.1(a) shall not apply to any
information that (A) is or becomes known to the general public under circumstances involving no breach by Employee or others of the terms of this Section 4.1(a) or any other confidentiality obligation to the Company,
(B) is generally disclosed to third parties by the Company without restriction on such third parties, or (C) is approved for release by written authorization of an officer of the Company. 

(v)    Employee agrees that all files, documents, letters, memoranda, reports, records, data sketches,
drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, electronic or other tangible material containing information of the Company or of third parties provided to
Employee in the course of Employee’s employment with the Company, whether created by Employee or others, which shah come into Employee’s custody or possession, shall be and are the exclusive property of the Company to be used by Employee
only in the performance of Employee’s duties for the Company and shah not be copied or removed from the Company premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the
Company in the custody or possession of Employee shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) the termination of this Agreement. After such delivery, Employee shall not retain any such
materials or copies thereof or any such tangible property and shall, upon request, execute a certification confirming that fact, the content of which shall be satisfactory to the Company. 

(vi)    Employee agrees that Employee’s obligation not to disclose or to use information and materials
of the types set forth in this Section 4.1(a), and Employee’s obligation to return materials and tangible property set forth in Section 4.1(a)(v) above extends to such types of information, materials and tangible
property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to Employee. 

  
 4 

 (vii)    Employee acknowledges that the Company from
time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or
regarding the confidential nature of such work. Employee agrees to be bound by all such obligations and restrictions that are known to Employee and to take all action necessary to discharge the obligations of the Company under such agreements. 

(b)    Nonsolicitation. During the Term and for a period of twelve (12) months thereafter (the
“Restricted Period”), Employee shall not, either alone or in association with others, directly or indirectly (i) solicit, persuade, encourage or permit any organization directly or indirectly controlled by Employee to solicit,
persuade, or encourage, any employee of the Company to leave the employ of the Company; (ii) solicit for employment, hire or engage as an independent contractor, or permit any organization directly or indirectly controlled by Employee to
solicit for employment, hire or engage as an independent contractor, any person who is employed or engaged by the Company or who was employed by the Company in the six (6) months preceding the solicitation, hiring or engagement; and/or
(iii) solicit, divert or take away, the business or patronage of any of the clients, collaborators, licensees, customers or accounts or prospective clients, collaborators, licensees, customers or accounts, of the Company that were contacted,
solicited or served by the Company, to Employee’s knowledge, during the two (2) year period prior to the end of the Term. 

(c)    Noncompetition. Employee agrees to devote Iris full business time, attention and energies to the performance
of duties with the Company. During the Term and for the Restricted Period, Employee may not contract with any business or enterprise that researches, develops, manufactures, markets, or sells any product or service that is competitive or potentially
competitive with any other product or service that is or was researched, developed or commercialized by the Company with the assistance of Employee or competes with any product or service developed, manufactured, marketed or sold, or planned to be
developed, manufactured, marketed or sold, by the Company. The Company retains a right to contract with other companies and/or individuals for employment services without restriction. 

(d)    Nondisparagement. Employee agrees not to make negative comments or otherwise disparage the Company or any of
its Affiliates or any of their officers, directors, employees, shareholders, agents or products other than (i) in the good faith performance of Employee’s duties to the Company Group while Employee is employed by tire Company or any
of its Subsidiaries or Affiliates; (ii) in truthful testimony given in response to a lawful subpoena or similar court or governmental order; or (iii) good faith and truthful communications with a government agency. 

(e)    Inventions. 

(i)    All inventions, ideas, creations, discoveries, computer programs, works of authorship, data,
developments, technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created, written, designed or developed by Employee, in the course of
providing services to the Company pursuant to this Agreement (but not while providing services to The President and Fellows of Harvard College or another academic institution of which the Employee is an employee), solely or jointly with others or
under Employee’s direction and whether during normal business hours or otherwise, (A) during the Term if related to the business of the Company or (B) during or after the Term if resulting or directly derived from Proprietary
Information (collectively under clauses (A) and (B), “Inventions”), shall be the sole property of the Company. Employee hereby assigns to the Company all Inventions and any and all related patents, copyrights, trademarks, trade
names, and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere and appoints any officer of the Company as Employee’s 

  
 5 

 
duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. However, this paragraph shall not apply to Inventions which do not
relate to the business or research and development conducted or planned to be conducted by the Company at the time such Invention is created, made, conceived or reduced to practice and which are made and conceived by the Employee not during normal
working hours, not on the Company ‘ s premises and not using the Company’s tools, devices, equipment or Proprietary Information. Employee further acknowledges that each original work of authorship which is made by the Employee (solely or
jointly with others) within the scope of the Agreement and which is protectable by copyright is a “work made for hire,” as that term is defined in the United States Copyright Act. 

(ii)    Employee agrees that if, in the course of his employment, Employee intends or wishes to incorporate
into any Invention developed under this Agreement any preexisting invention, improvement, development, concept, discovery or other proprietary information owned by Employee or in which Employee has an interest (“Prior Inventions”),
(i) Employee will inform the Company, in writing before incorporating such Prior Inventions into any Invention, and (ii) upon such incorporation, the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable
worldwide license with the right to grant and authorize sublicenses, to make, have made, modify, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such Prior
Inventions, without restriction, including, without limitation, as part of or in connection with such Invention, and to practice any method related thereto. Employee will not incorporate any invention, improvement, development, concept, discovery or
other proprietary information owned by any third party into any Invention without the Company’s prior written permission. In the event that a Prior Invention to which Employee has an obligation to grant a license to the Company pursuant to the
foregoing clause (ii) has previously been assigned to The President and Fellows of Harvard College or another academic institution of which Employee is an employee and to which Employee had a preexisting obligation to assign such Prior
Invention, then in lieu of the grant of a license as provided in the foregoing clause (ii), Employee shall use his best efforts to secure for the Company a license to such Prior Invention on such terms as the Company may reasonably request. 

(iii)    Upon the request of the Company and at the Company’s expense, Employee shall execute such
further assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other
rights in the United States and in any foreign country with respect to any Invention. Employee also hereby waives all claims to moral rights in any Inventions. 

(iv)    Employee shall promptly disclose to the Company all Inventions and will maintain adequate and
current written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual reduction to practice of any Invention. Such written records shall be available to and remain
the sole property of the Company at all times. 
 (f)    Return of Company Property. On the Termination Date (or
at any time prior thereto at the Company’s request), Employee shall return all property belonging to the Company or its Affiliates (including, but not limited to, any Company-provided laptops, computers, cell phones, wireless electronic mail
devices or other equipment, or documents and property belonging to the Company). Employee shall, upon request, execute a certification confirming the return of all Company property, the content of which shall be satisfactory to the Company. 

  
 6 

 (g)    Acknowledgements. Employee hereby acknowledges and agrees
that the covenants set forth in Section 4.1(a) through Section 4.1(f) (collectively, such covenants, the “Restrictive Covenants”) are an integral part of this Agreement and but for the Restrictive Covenants,
the Company would not enter into this Agreement. Employee further agrees that (i) the Restrictive Covenants do not preclude Employee from earning a livelihood, nor do they unreasonably impose limitations on Employee’s ability to
earn a living; (ii) the potential harm to the Company Group of the non-enforcement of any provision of the Restrictive Covenants outweighs any potential harm to Employee of its enforcement by
injunction or otherwise; (iii) the terms of the Restrictive Covenants are reasonable and narrowly tailored to protect the Company Group’s protectable interests in its confidential information and other protectable business
relationships; and (iv) Employee has carefully read this Agreement and consulted with legal counsel of Employee’s choosing regarding its contents, has given careful consideration to the restraints imposed upon Employee by this
Agreement including the Restrictive Covenants incorporated herein, and is in full accord as to their necessity for the reasonable and proper protection of confidential and Proprietary Information of the Company Group now existing or to be developed
in the future. Employee expressly acknowledges and agrees that each and every restraint imposed by the Restrictive Covenants is reasonable with respect to subject matter, scope and time period. 

(h)    Enforcement. Employee agrees and acknowledges that: 

(i)    If, at the time of enforcement of this Section 4.1, a court of competent jurisdiction
determines that the restrictions stated herein are unreasonable under circumstances then existing, the Parties hereto agree that they shall substitute the maximum duration or scope that is reasonable under such circumstances for the stated duration
or scope, and that they shall revise the restrictions contained herein to cover the maximum duration or scope permitted by law. 

(ii)    Because Employee’s services are unique and because Employee has access to confidential
information and customer and other relationships, the Parties hereto agree that money damages would be an inadequate remedy for any breach of this Agreement, including this Section 4.1. Therefore, Employee agrees that in the event of a
breach or threatened breach of this Agreement, including this Section 4.1, the Company, its Subsidiaries and/or their respective successors shall be entitled to specific performance and/or injunctive or other relief without posting a
bond or other security. 
 (i)    Survival of Provisions. The obligations contained in Sections 4.1
and 4.2 hereof shall survive the Termination Date and shall be fully enforceable thereafter. 

4.2    Cooperation. Upon the receipt of reasonable notice from the Company (including outside counsel of the
Company), Employee agrees that while employed by the Company or any of its Subsidiaries or Affiliates and thereafter, Employee will respond and provide information with regard to matters in which Employee has knowledge as a result of Employee’s
employment with the Company, and will provide reasonable assistance to the Company , its Affiliates and their respective representatives in defense of any claims that may be made against the Company or its Affiliates, and will assist the Company and
its Affiliates in the prosecution of any claims that may be made by the Company or its Affiliates, to the extent that such claims may relate to the period of Employee’s employment with the Company (collectively, “Cooperation
Claims”); provided that if such cooperation is required after the Termination Date, such assistance shall be provided at times mutually agreed to in good faith between Employee and the Company taking into account Employee’s obligations
under any then-existing full-time business endeavors. Employee agrees to promptly inform the Company if Employee becomes aware of arty lawsuits involving Cooperation Claims that may be filed or threatened against the Company or its Affiliates.
Employee also agrees to promptly inform the Company (to the extent that Employee is legally permitted to do so) if Employee is asked to assist in any investigation of the Company or its Affiliates (or their actions) or another party attempts to
obtain 

  
 7 

 
information or documents from Employee (other than in connection with any litigation or other proceeding in which Employee is a
party-in-opposition) with respect to matters Employee believes in good faith to relate to any investigation of the Company or its Affiliates, in each case, regardless of
whether a lawsuit or other proceeding has then been filed against the Company or its Affiliates with respect to such investigation, and shall not do so unless legally required. During the pendency of any litigation or other proceeding involving
Cooperation Claims, Employee shall not communicate with anyone (other than Employee’s attorneys and tax and/or financial advisors and except to the extent that Employee determines in good faith is necessary in connection with the performance of
Employee’s duties hereunder) with respect to the facts or subject matter of any pending or potential litigation or regulatory or administrative proceeding involving the Company or any of its Affiliates without giving prior written notice to the
Company or the Company’s counsel. The Company shall reimburse Employee for all reasonable out-of-pocket expenses incurred by Employee in fulfilling Employee’s
obligations under this Section 4.2 after presentation of appropriate documentation related thereto. 

4.3    Representations. Employee represents and warrants that Employee has disclosed to the Company, and provided
copies of, any agreement Employee may have with any third party (e.g., a former employer) which may limit Employee’s ability to work for the Company, or which otherwise would create a conflict of interest with the Company. Employee further
represents and warrants that Employee is not bound by any non-competition, non-disclosure, non-solicitation, or other
obligations, except for those contained in written agreements Employee has provided to the Company. Employee understands that Employee is prohibited from using or disclosing any confidential information or materials, including trade secrets, of any
former employer or third party to whom Employee has an obligation of confidentiality and from violating any lawful agreement that Employee may have with any third party. By accepting employment with the Company, Employee represents that Employee has
and will continue to comply with these requirements and that Employee is not in possession of any confidential documents or other property of any former employer or other third party. 

ARTICLE V 
 GENERAL
PROVISIONS 
 5.1    Notices. Any and all notices, consents, documents or communications provided for in this
Agreement shall be given in writing and shall be personally delivered, sent by facsimile or electronic mail (e-mail) transmission, mailed by registered or certified mail (return receipt requested) or sent by
courier, confirmed by receipt, and addressed as follows (or to such other address as the addressed Party may have substituted by notice pursuant to this Section 5.1): 

(a)    If to the Company: 

Nuvalent, Inc. 
 Attention: Matt
Shair 
 E-mail: MShair@Nuvalent.com 

With a copy to Cam Wheeler 

E-mail: CWheeler@Deerfield,com 

(b)    If to Employee: 

At Employee’s home address kept on file at the Company’s office or by e-mail to the e-mail address issued by the Company; provided that e-mail to such Company-issued address shall not be treated as sufficient notice after the Termination Date. 

  
 8 

 Such notice, consent, document or communication shall be deemed given upon personal
delivery, delivery by electronic mail (e-mail) transmission or receipt at the address of the Party stated above or at any other address specified by such Party to the other Party in writing, except that if
delivery has not been confirmed, then such notice shall be deemed given on the second business day after it is sent by FedEx or UPS overnight delivery. 

5.2    Entire Agreement. This Agreement contains the entire understanding and the full and complete agreement of
the Parties and supersedes and replaces any prior understandings and agreements among the Parties (or any predecessor to a Party), with respect to the subject matter hereof. This Agreement shall be executed in any number of counterparts, each of
which shall be deemed an original but all of which together shall constitute one and the same agreement. 
 5.3    
Amendment. This Agreement may be altered, amended, waived or modified only in a writing signed by both of the Parties hereto. Headings included in this Agreement are for convenience only and are not intended to limit or expand the rights of
the Parties hereto. References to Sections herein shall mean sections of the text of this Agreement, unless otherwise indicated. 

5.4     Assignability. This Agreement and the rights and duties set forth herein may not be assigned by Employee,
but may be assigned by the Company, in whole or in part. This Agreement shall be binding on and inure to the benefit of each Party and such Party’s respective heirs, legal representatives, successors and assigns. 

5.5     Severability. This Agreement contains several separate covenants. If any court of competent jurisdiction
determines that any covenant or provision of this Agreement is invalid or unenforceable, then such invalidity or unenforceability shall have no effect on the other covenants or provisions hereof, which shall remain valid, binding and enforceable and
in full force and effect, and such invalid or unenforceable provision shall be construed in a manner so as to give the maximum valid and enforceable effect to the expressed intent of the Parties. 

5.6     Waiver of Breach. The waiver by either Party of the breach of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach by either Party. 
 5.7    Governing Law. This
Agreement shall be governed by the laws of the State of Delaware, without regard to any rules of construction concerning the draftsman hereof and without regard to such state’s conflict of laws principles. 

5.8    Arbitration. If any dispute should arise concerning the breach, termination, enforcement, interpretation or
validity of this Agreement (including the determination of the scope or applicability of this agreement to arbitrate) or otherwise relating in any way to the terms and conditions of Employee’s employment, including any statutory claim of
discrimination, the parties agree to submit the dispute to arbitration before a panel of three (3) neutral arbitrators at JAMS in New York, New York pursuant to the JAMS Comprehensive Arbitration Rules and Procedures. Each party will bear its
own expenses, including legal and accounting fees, if any, with regard to arbitration. Any costs, fees or taxes involved in enforcing the arbitration award shall be fully assessed against and paid by the party resisting enforcement of the award. For
injunctive relief, it is agreed that any court of competent jurisdiction may also entertain an application by either party. The parties further agree that no demand for punitive damages shall be made in any arbitration proceeding. Any award of the
arbitrator shall be final and binding on the parties, subject only to such right of review that may lie under applicable law, and may be entered and enforced in any 

  
 9 

 
court having jurisdiction thereof. The parties agree for themselves and any persons or companies under their control and direction that any arbitration conducted under the authority of this
Agreement will be private and confidential, and all documents, evidence, orders and awards, whether electronic or otherwise, will be kept private and secret and will not be disclosed to persons who are not participating in the arbitration
proceeding. This obligation continues during the course of the proceeding and thereafter unless all parties otherwise agree in writing to the contrary. 

5.9    No Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the
parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party. Unless otherwise expressly provided, the words “include” and “including” mean including and not limited to.

 5.10    Counterparts. This Agreement shall be executed simultaneously in any number of counterparts, each of
which shall be deemed an original but all of which together shall constitute one and the same agreement. 

5.11    Tax Matters. 

(a)    Withholding. All payments and benefits to Employee, whether under this Agreement or otherwise, shall be
subject to withholding for income and employment taxes in the amount determined by the Company. Regardless of the amount withheld, Employee shall be responsible for all income and employment taxes owed with respect to amounts earned, accrued, or
payable under this Agreement (including imputed income), except to the extent applicable law specifies that the tax is the responsibility of the Company or another party. 

(b)    Section 409A. This Agreement shall be construed insofar as possible for all payments to
be exempt from Section 409A of the Code (“Section 409A”). and with respect to any amounts that are not so exempt, so as to avoid the imposition of additional tax and/or penalties under Section 409A. Any
payments that are subject to Section 409A shall be subject to the following: (i) amounts conditioned upon execution of a release shall not be paid before the year in which the last possible date for revocation of the release occurs
(measured from the Termination Date), even if the release is actually signed and the revocation period actually expires in an earlier year; (ii) in no event shall amounts subject to reimbursement be reimbursed after the year in which the
reimbursable expense is incurred; and (iii) to the extent payment of an amount is triggered by termination of employment, “termination of employment,” Termination Date, and similar terms shall mean “separation from service”
within the meaning of Section 409A and applicable regulations. For purposes of Section 409A, each installment in a series of installment payments shall be treated as a separate and distinct payment. 

[Signature Page Follows] 

  
 10 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year written
above. 
  

			
	COMPANY:
	
	NUVALENT, INC.

 
			
		
	 By:
	 	 /s/ Michael Farrell

			
	 Name:
	 	 Michael Farrell

	 Title:
	 	 Treasurer

	
	EMPLOYEE:
	
	 /s/ James Malone

James Malone

 Signature Page to Employment Agreement 

 Exhibit A 

Additional Defined Terms 

“Affiliate” of any Person means any Person that directly or indirectly controls, is controlled by, or is under common control
with the Person in question. 
 “Cause” shall be determined by the Board in its sole discretion and shall include the
following: (a) Employee’s willful and material failure to perform his duties to the Company (other than any such failure or refusal resulting from Employee’s incapacity); (b) Employee’s commission of an act of fiduciary breach
relating to the property of the Company and/or its Affiliates; (c) Employee’s gross misconduct; or (d) Employee’s material breach of the Agreement or any material written Company policy. Solely with respect to clauses
(a) and (d) above, Employee shall have thirty (30) days after receipt of notice from the Company of the events or conditions constituting Cause within which to cure such events or conditions constituting Cause, and Cause shall not be
deemed to exist unless and until Employee fails to cure such acts constituting Cause within such thirty (30) day cure period, 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Company Group” means the Company and any of its Subsidiaries. 

“Disability” or “Disabled” means the inability of Employee, due to a physical or mental impairment, for 120
days (whether or not consecutive) during any period of 360 days to perform the duties and functions contemplated by this Agreement. A determination of disability shall be made by the Company in consultation with a physician satisfactory to the
Company, and Employee shall cooperate with the efforts to make such determination, Any such determination shall be conclusive and binding on the Parties. 

“Governmental Authority” means any nation or government, any state, provincial or other political subdivision thereof, any
entity exercising executive, legislative, judicial, quasi-judicial, regulatory or administration functions of or pertaining to government, including any government authority, agency, department, board, commission or instrumentality of the United
States, any foreign government, any State of the United States or any political subdivision thereof, and any court, tribunal or arbitrators) of competent jurisdiction. 

“Person” means an individual, a partnership, a corporation, a limited liability company, an association, a trust, a joint
stock company, a joint venture, an unincorporated organization, any other business entity or a Governmental Authority. 

“Proprietary Information” includes all information, whether or not in writing, whether or not patentable and whether or not
copyrightable, of a private, secret, sensitive or confidential nature, owned, possessed or used by the Company, concerning the Company’s business, business relationships or financial affairs, including, without limitation, any Invention,
formula, vendor information, customer information, apparatus, equipment, trade secret, process, research, report, technical or research data, clinical data, know-how, computer program, software, software
documentation, hardware design, technology, product, processes, methods, techniques, formulas, compounds, projects, developments, marketing or business plan, forecast, unpublished financial statement, budget, license, price, cost, customer, supplier
or personnel information or employee list that is communicated to, learned of, developed or otherwise acquired by the Employee in the course of Employee’s employment with the Company. 

“Subsidiary” means, with respect to any Person, any corporation, limited liability company, partnership, association or
business entity of which (a) if a corporation, a majority of the total voting power 

  
 A-1 

 
of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly
or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (b) if a limited liability company, partnership, association or other business entity (other than a corporation), a majority of
partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by any Person or one or more Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons shall be
deemed to have a majority ownership interest in a limited liability company, partnership, association or other business entity (other than a corporation) if such Person or Persons shall be allocated a majority of limited liability company,
partnership, association or other business entity gains or losses or shall be or control any managing director or general partner of such limited liability company, partnership, association or other business entity. For purposes hereof, references
to a “Subsidiary” of any Person shall be given effect only at such times that such Person has one or more Subsidiaries, and, unless otherwise indicated, tire term “Subsidiary” refers to a Subsidiary of the Company. 

“Termination Date” means the date on which Employee ceases to be employed by the Company or its Subsidiaries for any reason
or no reason. 

  
 A-2EX-10.11

 Exhibit 10.11 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

NUVALENT, INC. 

AMENDED AND RESTATED REVENUE SHARING AGREEMENT 

THIS AMENDED AND RESTATED REVENUE SHARING AGREEMENT (this “Agreement”) is made and entered into as of February 2, 2017
(the “Effective Date”) by and between Nuvalent, Inc., a Delaware corporation (the “Company”), and Matthew Shair, Ph.D. (the “Founder”). 

WHEREAS, the Company and the Founder have previously entered into a Revenue Sharing Agreement dated as of February 2, 2017 (the
“Prior Agreement”) in order to induce the Founder to assign the Foundational IP to the Company and to devote his time and energy to the research and development needs of the Company; and 

WHEREAS, the Company and the Founder now desire to amend and restate the Prior Agreement in its entirety; 

NOW THEREFORE, in consideration of the foregoing recitals, the mutual promises and covenants set forth in this Agreement and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows: 

1. For purposes of this Agreement, the following terms shall have the following definitions. 

“Affiliate” shall mean with respect to a party, an entity that, directly or indirectly through one (1) or more
intermediaries, controls, is controlled by or is under common control with such party, other than any entity that would otherwise be deemed an “Affiliate” hereunder due to such entity being under the control of any entity or group of
entities (including Deerfield) affiliated with Deerfield Management, L.P. In this definition, “control” means: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares
having the right to vote for the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the
power to direct the management and policies of such entities. 
 “Business Relationship” means that the Founder
(i) serves on the Board of Directors of the Company, unless Founder is no longer entitled to designate a person for election to the Board of Directors of the Company due to a failure to satisfy the Founder Ownership Condition (as defined in
that certain Voting Agreement by and among the Company, Founder and Deerfield dated as of February 2, 2017, as such agreement may be amended or amended and restated from time to time (the “Voting Agreement”)) other than such a
failure due to sales by Founder of Founder’s Common Stock (as defined in the Voting Agreement) and (ii) provides services to the Company as a consultant or employee, unless such services are terminated by the Company without Cause.

 “Cause” shall exist upon (i) a good faith finding by the Board of
Directors of the Company (A) of repeated and willful failure of the Founder after written notice to comply with the material terms of the Consulting Agreement (including failure to provide the Services as defined therein), or (B) that the
Founder has engaged in dishonesty, gross negligence or misconduct, which dishonesty, gross negligence or misconduct has had a material adverse effect on the business affairs of the Company; (ii) the conviction of the Founder of, or the entry of
a pleading of guilty or nolo contendere by the Founder to, any crime involving moral turpitude or any felony; or (iii) a breach by the Founder of any material provision of any written agreement, written policy or written obligation with the
Company to which the Founder is a party relating to assignment of inventions, non-disclosure of confidential or proprietary information, non-competition and/or non-solicitation, which breach is not cured within thirty (30) days after written notice thereof. 

“Company Product” shall mean a pharmaceutical product that either (a) has a mechanism of action of inhibition of activity of
ROS1 and contains the compound that is the Company development candidate known as NVL-520 or a backup compound substituted therefor in the event of a product development failure of NVL-520 or (b) has a mechanism of action of inhibition of activity
of ALK and contains the compound that is the Company development candidate known as NVL-655 or a backup compound substituted therefor in the event of a product development failure of NVL-655. 

“Consulting Agreement” shall mean that certain Consulting Agreement by and between the Company and the Founder dated
February 2, 2017. 
 “Deerfield” shall mean Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design
Fund, IV, L.P. 
 “First Commercial Sale” shall mean, with respect to a Company Product and a country, the first sale by the
Company or its Related Parties after all required licenses, registrations, authorizations and approvals have been received from the applicable regulatory authority for such country, of such Company Product in such country for use or consumption in
commerce. Sales for clinical trial purposes or compassionate, named patients or similar use shall not constitute a First Commercial Sale. 

“Foundational IP” means the know-how described on Exhibit A to this Agreement,
which know-how constitutes all of the intellectual property of the Founder relating to the Founder’s ideas regarding [***]. 

“Funding Agreement” shall mean that certain Research Funding Agreement entered into by Deerfield and the Company on
February 2, 2017, pursuant to which Deerfield has agreed to provide the Company with, among other things, capital to support the initial formation of the Company and the development of the Company’s executive team, scientific strategy and
business plan, as set forth therein. 

  
 2 

 “Net Sales” shall mean with respect to any Company Product, the gross
amounts invoiced or received by the Company and its Related Parties (each an “Invoicing Entity”) for sales of such Company Product anywhere in the world less the following deductions solely to the extent actually incurred or allowed
with respect to such sales, and solely to the extent such deductions from amounts invoiced or received are in accordance with GAAP applied consistently, and which are not already reflected as a deduction from the invoiced price: 

(a) charge-back payments, rebates, and fees granted or paid to managed health care organizations or to federal, state and local governments,
their agencies, and purchasers and reimbursors or to trade customers, in all cases in customary and reasonable amounts; provided that, any such amounts subsequently paid shall be included in “Net Sales” at the time of
payment; 
 (b) credits or allowances actually granted upon, or reimbursements for, damaged goods, rejections, or returns of such Company
Product, including returns of such Company Product in connection with recalls or withdrawals; 
 (c) freight out, postage, shipping, and
insurance charges for delivery of such Company Product, to the extent separately billed on the invoice; 
 (d) taxes or duties levied on,
absorbed, or otherwise imposed on and directly linked to the sale of such Company Product, including value-added taxes, or other governmental charges otherwise imposed upon the billed amount, as adjusted for rebates and refunds, to the extent not
paid by the third party and only to the extent such taxes, charges and other amounts are not reimbursed to the Invoicing Entity, but excluding all income taxes; 

(e) customary distribution fees allowed or paid to third party distributors, brokers, or agents for Company Product sales outside the United
States, other than amounts paid to sales personnel, sales representatives, and sales agents employed by such Invoicing Entity (or its Related Parties); 

(f) coupons, co-pay card discounts and other similar programs resulting in payments to end users; and

 (g) the actual amount of any write-offs for bad debt up to a total of [***] of such sales during the applicable period. 

If the Company or its Related Parties sells any Company Product in the form of a combination product containing (i) a Company Product and
(ii) one or more active ingredients that are not Company Products or a delivery device (whether such elements are combined in a single formulation and/or package, as 

  
 3 

 
applicable, or formulated and/or packaged separately but sold together for a single price) (a “Combination Product”), Net Sales of such Combination Product for the purpose of
determining the payment due to the Founder pursuant to this Agreement shall be calculated [***]. If, on a country-by-country basis, such other active ingredient or
ingredients or delivery device in the Combination Product are not sold separately in such country, but the Company Product component of the Combination Product is sold separately in such country, Net Sales for the purpose of determining the payment
due to the Founder under this Agreement for the Combination Product shall be calculated [***]. If, on a country-by-country basis, such Company Product component is not
sold separately in such country, Net Sales for the purpose of determining the payment due to the Founder under this Agreement for the Combination Product shall be [***]. Notwithstanding anything to the contrary in this definition, under no
circumstances shall the portion of Net Sales allocable to the Company Product in a Combination Product be [***] of the total Net Sales for such Combination Product. 

“Patent” shall mean any and all (a) U.S. or foreign patent applications, including all provisional applications,
substitutions, continuations, continuations-in-part, divisions, renewals, and all patents granted thereon, (b) U.S. or foreign patents, reissues, revalidations,
reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including supplementary protection certificates or the equivalent thereof, and (c) other form of government- issued right substantially
similar to any of the foregoing, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such
foregoing patents or patent applications. 
 “Related Party” shall mean (a) the Company’s Affiliates, and
(b) the Company’s and its Affiliates’ respective licensees and sublicensees. 
 “Revenue Share Term” shall
mean, with respect to a Company Product and a country, the period commencing on the First Commercial Sale of such Company Product in such country and terminating upon the later of (a) the twelfth (12th) anniversary after such First
Commercial Sale, or (b) the expiration of the last-to- expire Valid Claim included in the Subject IP that covers the manufacture, use, offer for sale or sale of such Company Product in such country. 

“Subject IP” shall mean those Patents that claim or cover a Company Product. 

“Valid Claim” shall mean (a) an issued and unexpired claim of a Patent that has not been revoked or held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, which is not appealable or has not been appealed within the time allowed for appeal, and which has not been abandoned, disclaimed, denied or
admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or (b) a claim of an application within the Subject IP that has been pending for less than five
(5) years from the original priority date. 

  
 4 

 2. Assignment of Foundational IP. The Founder hereby assigns to the Company
all of the Founder’s right, title and interest in and to the Foundational IP and appoints any officer of the Company as the Founder’s duly authorized attorney to execute, file, prosecute and protect the same before any government agency,
court or authority. Upon the request of the Company and at the Company’s expense, the Founder shall execute such further assignments, documents and other instruments as reasonably may be necessary or desirable to fully and completely assign all
Foundational IP to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect thereto. The Founder also hereby waives all claims
to moral rights in any Foundational IP. The Founder hereby represents and warrants that [***] he is the sole and exclusive owner of the Foundational IP, free and clear of liens, claims and encumbrances [***]. 

3. Revenue Sharing. In consideration of the Founder’s assignment of the Foundational IP, during the Revenue Share Term,
within one hundred twenty (120) calendar days of the end of each calendar year, the Company shall pay to the Founder a payment equal to [***] of Net Sales for the immediately preceding calendar year as set forth herein. The payments payable to
the Founder pursuant to the foregoing sentence shall be reduced, on a Company Product-by-Company Product and country-by-country basis, to [***] of the amounts otherwise due to the Founder pursuant to the foregoing sentence during any portion of the Revenue Share Term when at least one Valid Claim of the Subject IP
does not cover such Company Product in such country. 
 4. Payment Terms. Within sixty (60) days after the end of each
calendar quarter during the term of this Agreement following the First Commercial Sale of a Company Product, the Company shall furnish to the Founder a written report showing in reasonably specific detail (a) the sales of each Company Product
by Company or its Related Parties during such calendar quarter, (b) a calculation of Net Sales of each such Company Product, (c) the amount of taxes, if any, withheld to comply with applicable law; and (d) a calculation of payments
due to the Founder hereunder with respect to the foregoing, and (e) the exchange rates, if any, used in determining the Net Sales in U.S. dollars. With respect to sales of Company Products invoiced in U.S. dollars, the gross sales, Net Sales
and revenue share payable shall be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency other than U.S. dollars, all such amounts shall be expressed both in the currency in which the distribution is invoiced and in the U.S.
dollar equivalent. The U.S. dollar equivalent shall be calculated using the average of the exchange rate (local currency per U.S. $1) published in The Wall Street Journal, Western Edition, under the heading “Currency Trading” on the last
business day of each month during the applicable calendar quarter, or other commercially reasonable exchange rate(s) proposed by the Company and approved by the Founder, such approval not to be unreasonably withheld, conditioned or delayed. All
payments hereunder shall be made by the Company from a bank account domiciled in the United States of America, unless otherwise agreed in writing by the Founder. 

  
 5 

 5. Audit Rights. Until [***] after the expiration of the Revenue Share Term,
upon the written request of the Founder and not more than once in each calendar year (except in response to manifest error by the Company or an effort on the part of the Company to fraudulently under report Net Sales) and not more than once with
respect to any period audited (except in response to manifest error by the Company or an effort on the part of the Company to fraudulently under report Net Sales), the Company shall permit an independent certified public accounting firm selected by
the Founder, and reasonably acceptable to the Company, at the Founder’s expense, to have access during normal business hours to the financial records of the Company as may be reasonably necessary to verify the accuracy of the payment reports
provided under Section 4 and the payments made under Section 3 for [***] prior to the date of such request. If such accounting firm concludes that additional amounts were owed during the audited period, the Company shall pay such
additional amounts within [***] days after the date the Founder delivers to the Company such accounting firm’s written report so concluding, together with interest thereon as set forth in Section 6, calculated from the date that the
applicable payment should have been made to the Founder pursuant to the terms hereof. The fees charged by such accounting firm shall be paid by the Founder; provided, however, if such audit discloses that the additional payment payable by the
Company for the audited period is [***] of the amount of the payments that should have been made by the Company for that audited period, the Company shall pay the fees and expenses charged by the accounting firm. The Company shall have the right to
require that such accounting firm, prior to conducting such audit, enter into an appropriate non- disclosure agreement with the Company. 

6. Late Payments. Any amount owed by the Company to the Founder under this Agreement that is not paid when due, as set forth
herein, shall accrue interest at the rate of [***] above the then-applicable short-term three-month London Interbank Offered Rate (LIBOR) as quoted in the Wall Street Journal (or if it no longer exists, a similarly authoritative source) calculated
on a daily basis or, if lower, the highest rate permitted under applicable law. 
 7. Survival of Rights. This Agreement shall
survive (a) a cancellation or termination of the Consulting Agreement or the Funding Agreement and shall be considered an enforceable agreement, in its own right, in the event that the Consulting Agreement or the Funding Agreement is cancelled
or terminated and (b) a sale of the Company (including the sale of all or substantially all of the Company’s assets), and/or a sale of all or substantially all of the Subject IP. This Agreement shall be binding upon and inure to the
benefit of the Company’s successors in interest, assignees, and licensees, and the Founder’s administrators, heirs, and successors, and assigns. 

8. Miscellaneous. 

(a) Assignment. This Agreement may be assigned or otherwise transferred by the Founder without the consent of the Company,
including to a successor in interest in connection with the transfer or sale of all or substantially all of the Founder’s 

  
 6 

 
business to which this Agreement relates, whether by merger, sale of assets or otherwise. The Founder shall provide prompt written notice of any such assignment and shall provide to the Company a
written agreement of the successor agreeing to be bound by the terms of this Agreement. In addition, the Founder may, without the consent of the Company, assign or otherwise transfer his right to receive payments under this Agreement. The Company
may assign its obligation to make payments hereunder with respect to a Company Product in connection with the assignment or exclusive license of all or substantially all of the Company’s right, title and interest in and to all of the applicable
Subject IP. The Company may assign or transfer this Agreement in its entirety only in conjunction with the assignment or transfer of all of the Company’s right, title and interest in and to all Subject IP to the same assignee. 

(b) Waiver. The waiver of the breach of any provision of this Agreement shall not operate or be construed as a waiver of any
subsequent breach of the same or other provision hereof. 
 (c) Notices. All notices and other communications under this
Agreement shall be in writing and shall be given by personal or courier delivery, facsimile, first class mail, certified or registered with return receipt requested or reputable overnight delivery service for next business day delivery, and shall be
deemed to have been duly given upon receipt if personally delivered, delivered by courier or delivered by reputable overnight delivery service, on the date of transmission if transmitted by facsimile, or three (3) business days after mailing if
mailed, to the addresses of the Company and the Founder contained in the records of the Company at the time of such notice. Any party may change such party’s address for notices by notice duly given pursuant to this Section 8(c). 

(d) Entire Agreement. This Agreement (including, any Exhibits and Schedules hereto) constitutes the entire agreement and
understanding between the Company and the Founder with respect to the subject matter hereof, and supersedes the Prior Agreement, all other prior or contemporaneous proposals, oral or written, and all other communications between the between the
Company and the Founder with respect to such subject matter. 
 (e) Headings. The section headings used in this Agreement are
intended for convenience of reference and shall not by themselves determine the construction or interpretation of any provision of this Agreement. 

(f) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware,
excluding those laws that direct the application of the laws of another jurisdiction. 
 (g) Counterparts and Facsimile
Signatures. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile signature
(including signatures in Adobe PDF or similar format). 

  
 7 

 (h) Enforcement. If any portion of this Agreement is determined to be invalid
or unenforceable, such portion shall be adjusted, rather than voided, to achieve the intent of the parties to the extent possible, and the remainder shall be enforced to the maximum extent possible. 

[Remainder of Page Intentionally Left Blank; Signature Page Follows] 

  
 8 

 IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Revenue
Sharing Agreement as of the date set forth in the preamble hereto. 
  

			
	NUVALENT, INC.
		
	By:	 	 /s/ James Porter, Ph.D.

	Name:	 	James Porter, Ph.D.
	Title:	 	CEO
	
	FOUNDER
	
	 /s/ Matthew Shair, Ph.D.

	Matthew Shair, Ph.D.

 [Signature Page to Amended and Restated Revenue Sharing Agreement] 

 EXHIBIT A 

FOUNDATIONAL IP 
 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]